cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Motor Learning on a Sequence of Manual Motor Gestures of Increasing Complexity Through the Mental Practise

The main objective of this research is to evaluate and quantify successes and errors, as well as execution time, in a sequence of manual motor gestures of increasing complexity through mental practice training (observation of actions and motor imagery).

The motor programs stored in the procedural memory systems allow the generation of motor mental images without the need for an external stimulus, although it has been demonstrated that providing visual information, prior to a task of imagination, facilitates it and causes a greater neurophysiological activity than if it were done in an isolated manner. Some studies have shown that in the short term, in complex motor tasks of foot and hand in a coordinated manner, the action observation training provokes a greater motor learning compared to the motor imagery strategy.

However, these studies have only assessed short-term memory immediately after the intervention. No study has so far evaluated these improvements in motor learning through action observation training and motor imagery on consecutive days, nor has it been evaluated with short to medium-term follow-up.

It is therefore that there is a lack in the current scientific literature regarding which isolated method, without physical practice, of mental practice on motor learning is the most effective when exposed both on consecutive days, as well as to short-medium-term follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 60
* Healthy and with no pain subjects

Exclusion Criteria:

* Any cognitive impairment that hindered viewing of audiovisual material. Difficulty understanding or communicating.
* Presence of systemic pathology, Central Nervous System or rheumatic disease.
* Inadequate understanding of the Spanish language to follow instructions for measuring and treatment.
* Collaboration of pregnant women.
* Underage subjects
* Subjects with pain at the time of the study
Ion Channel Genetic Biomarkers: Diagnostic Capabilities in the Assessment of Bipolar Disorder

Genotype 164 adults to evaluate six selected single nucleotide polymorphisms (SNPs) (rs1006737, rs10994336, rs10994133, rs2238071, rs1051375, rs1024582) for use as a genetic biomarker to differentiate between bipolar depression and unipolar depression.

Adults ages 18-80 will be recruited if they are diagnosed with bipolar disorder, major depression, or have no mood symptoms. The adults will undergo a diagnostic interview, the Mini International Neuropsychiatric Interview (MINI) for the diagnosis. The subjects will also complete the Adverse Childhood Events Scale to evaluate for a genetic x environmental interaction in detecting bipolar disorder at initial assessment. Genotyping will be done by SNaPshot genotyping method and genetic sample will be collected via buccal swab.

Eligibility Criteria:
Inclusion Criteria:

* presenting to one of 4 Denver Metro Area clinics
* Subjects must fall into one of 3 diagnostic categories, bipolar, MDD, or no mood symptoms.

Exclusion Criteria:

* Inability to provide informed consent
* history of TBI
* history of untreated seizure disorder
* substance abuse in the last 8 hours
* moderate-severe substance abuse disorder diagnosed in the last 6 months
Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD)

The purpose of this study is to determine the safety and effectiveness of two separate procedures to treat gastroesophageal reflux disease (GERD) also known as heartburn. The two therapies are: 1) a banding procedure alone using the Cook® 6 Shooter™ Saeed Multi-Band Ligator or 2) a banding/shaving procedure called Endoscopic Mucosal Resection (EMR) using the Cook® Duette™ Multi-Band Mucosectomy device.


Eligibility Criteria:
Inclusion Criteria:

* Subject is 18 years of age or older.
* Typical symptoms of heartburn and/or regurgitation requiring daily PPI therapy.
* Subject agrees to participate and signs consent form.

Exclusion Criteria:

* Patient is pregnant.
* Patient has a hiatal hernia greater than 2cm.
* Presence of persistent daily solid food dysphagia, unplanned weight loss over ten pounds, esophageal bleeding, or vomiting more than once per week).
* Active medical condition that would preclude the subject from finishing this study.
* BMI \> 39.
Prevention of Fascial Dehiscence With Prophylactic Onlay Mesh in Emergency Laparotomies

Facial dehiscence elicit high morbidity and mortality. This complication may arise in more than 8.5% of high-risk patients. Addressing risk factors and optimizing surgical technique are guarded as mainstay measures for prevention, but their efficacy is questionable. The aim of this study is to analyze the influence of using a polypropylene onlay prophylactic mesh on the incidence of fascial dehiscence in emergency surgery and associated complications.

Fascial dehiscence is associated with high morbidity and mortality rates. It occurs in more than 8.5% of high-risk patients. Current preventive measures described are control of risk factors and optimization of surgical technique. Despite that, the incidence of such complication remained stable in the last decades, highlighting the low efficacy of such measures. Polypropilene onlay mesh has been used to avoid incisional hernias in selected elective patients, and could be useful in the prevention of fascial dehiscence. In emergency situations, especially in contaminated and infected surgical procedures, safety and efficacy of mesh is controversial. In this study the investigators aimed to evaluate the influence of polypropilene prophylactic onlay mesh on the incidence of fascial dehiscence in high-risk patients undergoing midline emergency laparotomy. As secondary outcome, the associated morbidity, including surgical site occurence, will be analyzed. The study design will be a randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* Emergency laparotomy by midline incision
* High risk for abdominal wound dehiscence: Risk index\*\* ≥ 4,0 or ≥ 2,2 in combination with at least one of the following: smoking, obesity, malnutrition or malignant neoplasia.

  * Risk index is the sum of values associated with high-risk characteristics, based in the risk score for abdominal wall dehiscence published by van Ramshorst et. al. in World Journal of Surgery, 2010 (Rotterdam risk model):

Age category (in years)

* 40-49: 0.4
* 50-59: 0.9
* 60-69: 0.9
* ≥70: 1.1

Male gender: 0.7

Chronic pulmonary disease: 0.7

Ascites: 1.5

Jaundice: 0.5

Anemia: 0.7

Emergency surgery: 0.6

Type of surgery:

* Gallbladder/bile duct 0.7
* Esophagus 1.5
* Gastroduodenum 1.4
* Small bowel 0.9
* Large bowel 1.4
* Vascular 1.3

Exclusion Criteria:

* Non-midline incisions or midline laparotomy measuring less than 1/4 the distance between the xyphoid and the pubis, including laparoscopic surgery.
* Diagnosis of incisional hernia or presence of previous mesh on site.
* Midline laparotomy performed in less than 30 days.
* Pregnancy
* Severe trauma with hemodynamic instability
* Need for open abdomen or relaxing incisions
* Need for re-laparotomy during the first 30 postoperative days, except cases in which an abdominal wall dehiscence was diagnosed.
* Death during the first 30 postoperative days, except cases in which an abdominal wall dehiscence was diagnosed before the event.
Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study objectives which include PK, safety monitoring for maternal and fetal/infant safety signals, and adherence.

Study participants will be randomized to one of two parallel study arms, involving dosing of tenofovir disoproxil sodium/emtricitabine (TDF/FTC). The investigators will be recruiting and enrolling in the late 1st (preferred) and 2nd trimesters of pregnancy to capture the changes in kidney function and blood flow through the kidneys that appear to start in the late 1st trimester and are most significant in the 2nd and 3rd trimesters of pregnancy. Given the unknown time frame for the return to pre-pregnancy physiologic state and the increased risk of HIV acquisition postpartum, participants will be continued on study dose PrEP until after participants' 1-3 week postpartum visit, after which all participants will be dispensed standard dose PrEP. A 6-12 week postpartum study visit will also be performed to evaluate the timing of return to non-pregnant plasma drug levels during the postpartum period.

PK Sampling. Primary PK data will be derived from up to 7 study visits with PK sampling, including two PK visits in each trimester and postpartum. All PK visits sample blood before an observed PrEP dose. .

Safety Sampling. Maternal safety assessments will continue until 6 months postpartum. Fetal evaluation includes non-invasive limited ultrasound (US) and biophysical profiles (BPP) at study visits and 2nd and 3rd trimester interval growth US, and chart review of all before birth assessments. At birth, the investigators will obtain cord blood plasma to assess for mitochondrial function. Infant safety assessments will continue until 1 year of life. Infants will undergo swaddled Dual-energy X-ray absorptiometry (DXA) scans (without sedation) at 3-6, 24-28, and 50-54 weeks of age. The investigators will assess kidney function by blood sample at 3-6 weeks of life and repeated at 24-28 weeks.

Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older
* Able to speak English, French, or Spanish
* Able and willing to provide written informed consent
* Viable first (preferable) or second trimester intrauterine pregnancy
* Creatinine clearance \>70 ml/min
* Negative HIV test and no signs/symptoms of acute HIV infection,
* Documented negative hepatitis B virus status.

Exclusion Criteria:

* HIV positive at any time in the study. All neonates of mothers participating in the trial will be recruited, regardless of gestational age at delivery or congenital anomalies/comorbidities.
Life-Steps Counseling to Enhance Adherence and Engagement in PrEP Care

The purpose of this study is to test how different types of interventions may affect how someone takes their pre-exposure prophylaxis (PrEP) medication.


Eligibility Criteria:
Inclusion Criteria:

1. Age: 18 years or older
2. Male sex at birth or trans man (current gender identity is male) assigned female sex at birth
3. Self-reports as a person who has sex with men
4. PrEP naïve or is currently prescribed PrEP and reports uncertainty about future adherence
5. Medical providers at each site will determine that the participant is indicated for PrEP per Centers for Disease Control (CDC) guidelines
6. Screens in for currently having one or more of the following psychosocial syndemic problems: depression; heavy alcohol use; problematic substance use or polydrug use; history of trauma or abuse; and/or current interpersonal violence
7. Owns a cell phone that has texting and internet / data capacity

Exclusion Criteria:

1. Unable to provide informed consent due to severe mental or physical illness, cognitive impairment, or substance intoxication at the time of interview
2. Discovery of active suicidal ideation or major mental illness (e.g. untreated psychosis or mania) at the time of enrollment (these patients will be referred immediately for treatment, but may join the study when this is resolved)
3. Laboratory or clinical findings that would preclude PrEP initiation (e.g. decreased creatinine clearance)
Lung and Gut Microbiome in Chronic Obstructive Pulmonary Disease

Increasing evidence have implied that microbiota from airway and gut might be involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the cross-talk between respiratory and gastrointestinal microbiome in COPD is still undetermined. The study is aimed to investigate the interaction between lung and gut flora, and their role in the process of COPD.

Despite the high prevalence of chronic obstructive pulmonary disease (COPD), there continues to be a large gap in our understanding of disease pathogenesis and mechanisms accounting for large variability in disease phenotype. Cigarette smoking is the principal cause of COPD, but only approximately 15% of adults with substantial tobacco exposure develop clinical COPD. Besides, bacterial colonization or infection is also considered as an important factor in COPD. There are very limited data from microbiome studies that suggest that respiratory and gastrointestinal microbiota may be involved in the pathogenesis of COPD. However, the cross-talk between between lung and gut microbiome, and their relationship with various clinical phenotypes of COPD. Here, we conducted 16S rRNA-based pyrosequencing to evaluate the link between the lung-gut axis and the clinical phenotypes of COPD, such as lung function, emphysema, symptoms, exacerbations, inflammation levels and metabolic features.

Eligibility Criteria:
Inclusion Criteria:

1. males aged 40-80;
2. diagnosed with COPD according to the GOLD guidelines;
3. clinically stable patients without medication changes or exacerbation in two months;
4. smoking history of more than 10 pack years

Exclusion Criteria:

1. diagnosed with unstable cardiovascular diseases, significant renal or hepatic dysfunction or mental incompetence;
2. diagnosed with asthma, active pulmonary tuberculosis, diffuse panbronchiolitis, cystic fibrosis, clinically significant bronchiectasis, exacerbation of COPD or pneumonia in two months;
3. prescribed immunosuppressive medications.
Effects of Cervical Spine Retraction Exercise With and Without Diaphragmatic Breathing in Forward Head Posture.

This study aims to determine the effect of combining diaphragmatic exercises with cervical retraction exercise on pain, disability, active range of motions of cervical spine and craniovertebral angle in individuals with forward head posture.

Forward head posture altering breathing pattern is one of the most common musculoskeletal deformity. Diaphragmatic exercises can reduce pain and disability levels, and correct forward head posture (FHP) in patients with neck discomfort.

In this randomized clinical trial, fifty two participants displaying forward head posture (FHP) will be randomly assigned to one of the two intervention groups: the Diaphragmatic Exercises and Cervical Retraction Exercise Combined Group or the Cervical Retraction Exercise Alone Group. Randomization will be performed using a convenient random sampling method via sealed opaque envelopes. Each participant will receive a total of twelve treatment sessions over a four-week period. The efficacy of the interventions will be assessed at the beginning (first session), conclusion (twelfth session), and two weeks after completing the sessions. Outcome measures, including pain intensity, disability levels, cervical range of motion, and craniovertebral angle (CVA), will be evaluated using the Numeric Pain Rating Scale (NPRS), Neck Disability Index (NDI), universal goniometer and Image J software, respectively. Data will be analyzed using Statistical Package for the Social Sciences (SPSS) software version 26. Normality of data will be assessed using the Kolmogorov-Smirnov test. For within-group comparisons, either repeated measures ANOVA or the Friedman test will be used. To compare changes between the groups, the independent t-test or Mann-Whitney U test will be applied, depending on the data distribution. The analysis of these outcome measures will provide valuable insights into the impact of the interventions on participants' symptoms and postural alignment.

Eligibility Criteria:
Inclusion Criteria:

* Primary complaint of neck pain (pain on the posterior part of the cervical spine to the beginning of the thoracic area with or without pain in the shoulder girdle)
* Age from 20 to 35 years
* Both gender
* CVA \<49° (16)

Exclusion Criteria:

* Any serious pathology such as tumor
* Had history of whiplash injury within 3 months of the examination,
* Underwent prior surgery to the cervical spine
* Currently using muscle relaxation medication.
* Degenerative conditions
* Exhibited positive neurologic signs consistent with nerve root compression.
* Patients with a history of respiratory disease, such as repeated bronchitis, pneumonia, asthma, pulmonary lymph nodes, pleurisy, cured tuberculosis and others
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

Toxicity of anti-IL-5

The purpose of the study is to assess the toxicity of anti-IL-5, and to see whether it lowers peripheral blood eosinophils and/or tissue and whether it has a steroid and/or interferon sparing effect.

Eligibility Criteria:
Inclusion Criteria:

* Adequate renal, cardiac, and hepatic function
* Not pregnant or breastfeeding
* A diagnosis of hypereosinophilic syndrome such as:

  * Idiopathic hypereosinophilic syndrome;
  * Eosinophilia myalgia syndrome;
  * Eosinophilic gastroenteritis;
  * Churg-Strauss syndrome;
  * Eosinophilic cellulitis;
  * Benign hypereosinophilia; or
  * Eosinophilic esophagitis.
* Maintained on, or in need of, the following: glucocorticoids, interferon, methotrexate, hydroxyurea, cytoxan, 6-mercaptopurine, or vincristine
* Blood eosinophil counts greater than 750 cells/mcl

Exclusion Criteria:

* Creatinine \> 3 X upper limit for age
* AST \> 5 X upper limit for age
* Platelet count \< 50,000/mm3
* Cardiac function:

  1. NYHA class IIIb or IV (patients with shortness of breath or fatigue with mild exertion or at rest);
  2. Patients with symptomatic supraventricular or ventricular arrythmias requiring treatment;
  3. Patients requiring IV heart failure medications;
  4. Angina or acute myocardial infarction
* History of renal, hepatic, endocrine, oncologic, cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the patient or impact on the validity of the study results
* History of allergic or adverse response to previous antibody type therapy
* History of allergic or adverse response to anti-IL-5 therapy
* Evidence of, or history of, a parasitic infection (within past 1 year)
* Participation in a previous clinical trial involving an investigational agent within 30 days prior to study initiation
* Receipt of anti-IL-5 therapy in the past
* Blood donation of 450 ml (1 pint) or more within 30 days prior to study initiation
* Abnormal or unusual diet or substantial changes in eating habits within 30 days prior to, or during, the study.
* Patients who do not have eosinophil levels \> 750 cells/mcl after the run-in period. Patients who have only eosinophilic infiltration of tissue are eligible if they do not develop an eosinophil level \> 750 cells/mcl, assuming that they meet all other eligibility requirements.
* Positive serum pregnancy test
* Breastfeeding
* Unable to use effective birth control methods for duration of study
* Unable or unwilling to give voluntary informed consent/assent
Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit

Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.

There are still many barriers to screening and linkage to care for patients having somatic illness.

Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.

The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.

Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.

There are still many barriers to screening and linkage to care for patients having somatic illness.

Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.

Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results.

The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit.

Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.

Eligibility Criteria:
Inclusion criteria

* adults ≥18 years
* having a psychiatric condition and hospitalized in a psychiatry unit of CHU Montpellier , France
* patients who lack capacity of consent if legal representative consents
* involuntary psychiatric hospitalization, if consent is given

Exclusion criteria

* lack of written consent
* Unable to understand nature and objective of the methodology
* Pregnant or breast feeding woman
* Not affiliated with a French social security
Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve)

This is an open label, non-randomized, prospective, multicenter study.


Eligibility Criteria:
Inclusion Criteria:

Patients for this study must meet the following inclusion criteria to be eligible for enrollment:

1. The patient is \>18 years of age.
2. Patient is considered a candidate for the IVCF under one of the following indications:

   * Proven PE
   * Recurrent PE despite adequate anticoagulation
   * Contraindication to anticoagulation
   * Inability to achieve/maintain therapeutic anticoagulation
   * Iliocaval DVT
   * Large, free-floating proximal (i.e. ileofemoral) DVT
   * Massive PE treated with thrombolysis/thrombectomy
   * Chronic PE treated with thrombectomy
   * Protection during thrombolysis for iliocaval DVT
   * PE with limited cardiopulmonary reserve
   * Poor compliance with anticoagulant medications
   * High risk of injury worsened by anticoagulation (e.g., ataxia, falls)
   * Multi-trauma patient with high risk of PE
   * Surgical patients at high risk of PE
   * Medical condition with high risk of PE
3. Patient has a vena cava diameter of 17-28mm.
4. The patient or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent.
5. The patient is willing to be available for the appropriate follow-up for the duration of the study.
6. The patient has suitable IVC anatomy that would allow infra-renal placement of the filter.

Exclusion Criteria:

Patients who have ANY of the following exclusion criteria are NOT eligible for the study:

1. The patient has one of the following conditions:

   * Renal vein thrombosis
   * IVC thrombosis extending to renal veins
   * Duplicate IVC
   * Gonadal vein thrombosis
   * Requires supra-renal filter placement
2. The patient has an uncontrolled infectious disease.
3. The patient is at risk for aseptic PE.
4. Patient has uncontrollable coagulopathy.
5. Patient has an existing IVCF.
6. The patient has a life expectancy of less than 6 months.
7. The patient is pregnant.
8. The patient has a condition that inhibits radiographic visualization of the IVC.
9. The patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol.
10. The patient has a known hypersensitivity to contrast which cannot be pre-treated.
11. The patient's access vessels preclude safe insertion of the delivery system.
12. The patient is participating in another device or drug study. Patient must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this trial. The patient may only be enrolled in this study once.
13. The patient is unable and/or unwilling to cooperate with study procedures or required follow-up visits.